Compare Stocks

→ Nvidia Has a BIG Problem — Here’s Who Benefits MOST (From Weiss Ratings) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ERM EquityCompass Risk Manager ETF	$23.09 -0.2%	$23.09	$20.72 ▼ $23.15	$16.86M	0.83	4,740 shs	600 shs
FTSV Forty Seven	$95.51	$95.51	$5.53 ▼ $95.51	$4.60B	0.4	1.61 million shs	N/A
GCL Colabor Group	C$1.20 +1.7%	C$1.20	C$0.72 ▼ C$1.33	C$122.39M	0.76	100,094 shs	21,650 shs
LPC Lorne Park Capital Partners	C$1.35 +14.4%	C$1.15	C$0.95 ▼ C$1.38	C$73.53M	-0.04	3,935 shs	5,500 shs

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ERM EquityCompass Risk Manager ETF	0.00%	0.00%	0.00%	0.00%	+3.22%
FTSV Forty Seven	0.00%	0.00%	0.00%	0.00%	0.00%
GCL Colabor Group	-1.67%	-0.84%	+1.72%	+1.72%	+57.33%
LPC Lorne Park Capital Partners	0.00%	+14.41%	+17.39%	+8.00%	+3.85%

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ERM EquityCompass Risk Manager ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FTSV Forty Seven	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GCL Colabor Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LPC Lorne Park Capital Partners	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ERM EquityCompass Risk Manager ETF	0.00	N/A	∞	∞ Upside
FTSV Forty Seven	N/A	N/A	N/A	N/A
GCL Colabor Group	N/A	N/A	N/A	N/A
LPC Lorne Park Capital Partners	N/A	N/A	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ERM EquityCompass Risk Manager ETF	N/A	N/A	N/A	N/A	N/A	N/A
FTSV Forty Seven	$15.68M	293.33	N/A	N/A	$7.52 per share	12.70
GCL Colabor Group	C$659.13M	0.19	C$0.04 per share	29.60	C$1.06 per share	1.13
LPC Lorne Park Capital Partners	C$29.40M	2.50	C$0.11 per share	12.39	C$0.21 per share	6.43

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ERM EquityCompass Risk Manager ETF	N/A	N/A	14.17	∞	N/A	N/A	N/A	N/A	N/A
FTSV Forty Seven	-$87.62M	-$2.34	N/A	N/A	N/A	N/A	-50.38%	-44.35%	N/A
GCL Colabor Group	C$6.05M	C$0.06	20.00	∞	0.61	0.85%	5.72%	3.50%	5/1/2024 (Estimated)
LPC Lorne Park Capital Partners	C$1.84M	C$0.03	45.00	∞	N/A	6.25%	1.36%	4.16%	4/23/2024 (Estimated)

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ERM EquityCompass Risk Manager ETF	$0.35	1.52%	N/A	N/A	N/A
FTSV Forty Seven	N/A	N/A	N/A	N/A	N/A
GCL Colabor Group	C$0.24	20.00%	N/A	400.00%	N/A
LPC Lorne Park Capital Partners	C$0.03	2.22%	N/A	100.00%	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ERM EquityCompass Risk Manager ETF	N/A	N/A	N/A
FTSV Forty Seven	N/A	14.81	14.81
GCL Colabor Group	158.98	1.74	0.76
LPC Lorne Park Capital Partners	34.86	0.69	1.93

Ownership

Institutional Ownership

Company	Institutional Ownership
ERM EquityCompass Risk Manager ETF	N/A
FTSV Forty Seven	71.77%
GCL Colabor Group	12.04%
LPC Lorne Park Capital Partners	N/A

Insider Ownership

Company	Insider Ownership
ERM EquityCompass Risk Manager ETF	N/A
FTSV Forty Seven	37.40%
GCL Colabor Group	25.03%
LPC Lorne Park Capital Partners	57.55%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ERM EquityCompass Risk Manager ETF	N/A	730,000	N/A	Not Optionable
FTSV Forty Seven	57	48.16 million	N/A	Not Optionable
GCL Colabor Group	729	101.99 million	N/A	Not Optionable
LPC Lorne Park Capital Partners	N/A	54.47 million	N/A	Not Optionable

FTSV, ERM, LPC, and GCL Headlines

No headlines for this company have been tracked by MarketBeat.com

Media Sentiment Over Time

Top Headlines

Consumer Sentiment Highest Since 2021, 3 Stocks Leading the Way
April 1, 2024 9:25 AM
View Consumer Sentiment Highest Since 2021, 3 Stocks Leading the Way
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
April 12, 2024 7:32 AM
View 2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Should You Buy Boeing Stock After CEO Resignation Announcement?
March 25, 2024 11:10 AM
View Should You Buy Boeing Stock After CEO Resignation Announcement?
Home Depot vs. Lowe's: The Home Improvement Stocks Heavyweights
April 2, 2024 7:02 AM
View Home Depot vs. Lowe's: The Home Improvement Stocks Heavyweights
2 Cannabis Stocks Clawing Back from the Grave, Germany Legalizes
March 25, 2024 7:00 AM
View 2 Cannabis Stocks Clawing Back from the Grave, Germany Legalizes

All Headlines

Company Descriptions

EquityCompass Risk Manager ETF

NYSEARCA:ERM

The EquityCompass Risk Manager ETF (ERM) is an exchange-traded fund that is based on the S&P 500 index. The fund is an actively-managed, long-only fund that provides long-term capital appreciation with capital preservation as a secondary objective. ERM was launched on Apr 10, 2017 and is managed by First Trust.

Forty Seven

NASDAQ:FTSV

Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.

Colabor Group

TSE:GCL

Colabor Group Inc., together with its subsidiaries, markets and distributes food and food-related products in Canada. It operates in two segments, Distribution and Wholesale. The Distribution segment offers frozen products, dry staples, dairy products, meat, seafood, fruits and vegetables, disposables, and sanitation products, as well as fish products. This segment serves restaurants, hotels, foodservice operators, specialty food stores, healthcare institutions, schools and universities, and other retail customers. The Wholesale segment provides food, food-related, and non-food products to distributors, food service, and retail industries. Colabor Group Inc. was founded in 1962 and is headquartered in Quebec, Canada.

Lorne Park Capital Partners

CVE:LPC

Lorne Park Capital Partners Inc., together with its subsidiaries, provides portfolio management services to investors, estates, trusts, endowments, and foundations in Canada and the United States. It also offers insurance agency services. The company was founded in 2009 and is based in Oakville, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial